Duchenne UK’s Project HERCULES awarded prestigious rare disease award

Nov 2, 2018

Written by Juliet Mumby-Croft, Director

Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments for Duchenne Muscular Dystrophy (DMD). It brings together eight leading pharmaceutical companies, academics, patient organisations and advisers to develop and build a better evidence base for DMD to aid the pricing and reimbursement stage of drug development. Source Health Economics are developing the core economic model for this collaboration.

This collaboration was recognised by the EURORDIS Black Pearl Company Award for Patient Engagement.


More Insights

HTA monthly – October 2025

HTA monthly – October 2025

By Kiera Lander   October brought real movement across the health technology assessment (HTA) landscape — not just in HealthTech, but across medicines, strategy, and international collaboration. From National Institute for Health and ... Read more

RAISE guidance – maintaining SLR standards in an AI-assisted future

RAISE guidance – maintaining SLR standards in an AI-assisted future

Written by Gwennie Ogilby (Associate Systematic Review Analyst) and Tom Metcalf (Senior Systematic Review Analyst)   Systematic literature reviews (SLRs) are considered one of the strongest forms of evidence to guide healthcare ... Read more

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Thought Piece: How do we Reconcile Commoditisation and Strategic Value in Market Access?

Written by Dan Spacie, CEO of SCIRIS   Executive Summary Market access services are undergoing a dual transformation. On one hand, technological advances and procurement pressures are driving commoditisation—standardising deliverables and ... Read more

Newborn genome screening: implications for health technology assessments of new orphan drugs

Newborn genome screening: implications for health technology assessments of new orphan drugs

Written by Luke Parkes   Introduction Newborn screening (NBS) is an impactful public health initiative that enables the diagnosis of severe conditions in asymptomatic infants at birth. Typically, NBS programmes include testing for a ... Read more